Katharina Buesch1, Sarah Acaster2, Kate Williams3, Ian Davidson4, Mark Rance4. 1. PTC Therapeutics Switzerland GmbH, Tower 2, Turmstrasse 28, CH-6312, Steinhausen/Zug, Switzerland. 2. Acaster Lloyd Consulting Ltd, 16 Upper Woburn Place, London, WC1H 0BS, UK. 3. Acaster Lloyd Consulting Ltd, 16 Upper Woburn Place, London, WC1H 0BS, UK. kate.williams@acasterlloyd.com. 4. PTC Therapeutics Ltd, Building 2, Ground Floor, Guildford Business Park, Guildford, UK.
Abstract
BACKGROUND: Duchenne muscular dystrophy is a rare genetic neuromuscular disorder, which can result in early death due to disease progression. Ataluren is indicated for the treatment of nonsense mutation Duchenne muscular dystrophy, in ambulatory individuals aged two years and older. This study explored the impact of caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy, as well as the impact of treatment with ataluren on the caregiver experience, using retrospective recall. METHODS: Qualitative interviews were conducted with caregivers in the UK. Interviews were conducted by telephone, were recorded and transcribed. Data were analysed using thematic analysis and saturation was recorded. RESULTS: Ten interviews were conducted with parents of individuals aged 4-19 years. Caregivers reported proximal impacts (physical, emotional, time-related), and distal impacts (work, relationships, social life) of caring for their sons. The relationships between these impacts were illustrated in a conceptual model. Changes to the caregiver experience since initiation with their son's treatment were discussed. CONCLUSION: Caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy has a substantial multifaceted impact on caregivers. Treatments which have the potential to improve symptoms or delay progression, may also have a positive impact on the quality of life of caregivers.
BACKGROUND:Duchenne muscular dystrophy is a rare genetic neuromuscular disorder, which can result in early death due to disease progression. Ataluren is indicated for the treatment of nonsense mutation Duchenne muscular dystrophy, in ambulatory individuals aged two years and older. This study explored the impact of caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy, as well as the impact of treatment with ataluren on the caregiver experience, using retrospective recall. METHODS: Qualitative interviews were conducted with caregivers in the UK. Interviews were conducted by telephone, were recorded and transcribed. Data were analysed using thematic analysis and saturation was recorded. RESULTS: Ten interviews were conducted with parents of individuals aged 4-19 years. Caregivers reported proximal impacts (physical, emotional, time-related), and distal impacts (work, relationships, social life) of caring for their sons. The relationships between these impacts were illustrated in a conceptual model. Changes to the caregiver experience since initiation with their son's treatment were discussed. CONCLUSION: Caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy has a substantial multifaceted impact on caregivers. Treatments which have the potential to improve symptoms or delay progression, may also have a positive impact on the quality of life of caregivers.
Authors: Robert F Pangalila; Geertrudis A M van den Bos; Henk J Stam; N Job A van Exel; Werner B F Brouwer; Marij E Roebroeck Journal: Disabil Rehabil Date: 2011-12-09 Impact factor: 3.033
Authors: Joy Read; Maria Kinali; Francesco Muntoni; Timothy Weaver; M Elena Garralda Journal: Eur J Paediatr Neurol Date: 2010-08-21 Impact factor: 3.140
Authors: Christophe Pichavant; Annemieke Aartsma-Rus; Paula R Clemens; Kay E Davies; George Dickson; Shin'ichi Takeda; Steve D Wilton; Jon A Wolff; Christine I Wooddell; Xiao Xiao; Jacques P Tremblay Journal: Mol Ther Date: 2011-04-05 Impact factor: 11.454
Authors: Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore Journal: Eur J Health Econ Date: 2016-04-02
Authors: Erik Landfeldt; Peter Lindgren; Christopher F Bell; Michela Guglieri; Volker Straub; Hanns Lochmüller; Katharine Bushby Journal: Dev Med Child Neurol Date: 2015-10-19 Impact factor: 5.449
Authors: S Ryder; R M Leadley; N Armstrong; M Westwood; S de Kock; T Butt; M Jain; J Kleijnen Journal: Orphanet J Rare Dis Date: 2017-04-26 Impact factor: 4.123